Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Absci Corp (ABSI)

Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Absci Reports Tomorrow With Investors Still Waiting for the AI Drug Platform to Prove Itself Barchart - Wed May 6, 4:01PM CDT

Barchart Research What to Expect from ABSI Earnings ABSI Generated May 6, 2026 Current Price $5.95 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 7.52% Absci Reports Tomorrow With Investors...

ABSI : 5.95 (+6.06%)
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon May 4, 7:11PM CDT

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 5.95 (+6.06%)
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026 GlobeNewswire - Thu Apr 23, 3:05PM CDT

VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 5.95 (+6.06%)
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference GlobeNewswire - Wed Apr 8, 7:00AM CDT

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 5.95 (+6.06%)
Absci Reports Earnings Today: Can Biotech Upstart Prove Skeptics Wrong? Barchart - Tue Mar 24, 4:01PM CDT

ABSI : 5.95 (+6.06%)
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results GlobeNewswire - Tue Mar 24, 3:05PM CDT

Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201...

ABSI : 5.95 (+6.06%)
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic GlobeNewswire - Tue Mar 24, 7:00AM CDT

VANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 5.95 (+6.06%)
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 6, 3:05PM CST

VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 5.95 (+6.06%)
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer GlobeNewswire - Tue Mar 3, 7:00AM CST

Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue...

ABSI : 5.95 (+6.06%)
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 GlobeNewswire - Tue Feb 24, 7:00AM CST

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 5.95 (+6.06%)

Barchart Exclusives

Nebius Just Became a Serious Contender in AI Inference. It’s a Strong Buy Even at All-Time Highs. Barchart - 14 minutes ago
As the world moves from AI training to AI inference, Nebius Group is proactively taking the initiative to dominate the future of AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.